Back to results
Considerations for Assessment of Particles in Biologics Originating from Packaging and Standardization Initiatives
This presentation discusses risks caused by particles in parenteral drug products.
Particles originating from injectable primary packing components can cause harm to patients by: causing injection site irritation and occluding capillaries; impacting product sterility, affecting pharmaceutical quality; causing protein aggregation or product interaction, and increasing risk for immunogenicity.
Please Signup/Login to see the full article.Click here